AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price was up 1.8% during trading on Thursday . The company traded as high as $3.46 and last traded at $3.40. 100,018 shares were traded during trading, an increase of 538% from the average daily volume of 15,685 shares. The stock had previously closed at $3.34.
AlloVir Stock Up 0.9%
The firm has a market cap of $17.70 million, a PE ratio of -0.17 and a beta of 0.63. The company has a 50-day simple moving average of $4.43 and a two-hundred day simple moving average of $6.56.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Featured Stories
- Five stocks we like better than AlloVir
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
